JP2025513894A5 - - Google Patents

Info

Publication number
JP2025513894A5
JP2025513894A5 JP2024560753A JP2024560753A JP2025513894A5 JP 2025513894 A5 JP2025513894 A5 JP 2025513894A5 JP 2024560753 A JP2024560753 A JP 2024560753A JP 2024560753 A JP2024560753 A JP 2024560753A JP 2025513894 A5 JP2025513894 A5 JP 2025513894A5
Authority
JP
Japan
Prior art keywords
tapi
cell
polynucleotide
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065784 external-priority patent/WO2023201340A2/en
Publication of JP2025513894A publication Critical patent/JP2025513894A/ja
Publication of JP2025513894A5 publication Critical patent/JP2025513894A5/ja
Pending legal-status Critical Current

Links

JP2024560753A 2022-04-15 2023-04-14 細胞療法の免疫原性を低下させるための組成物及び方法 Pending JP2025513894A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263331773P 2022-04-15 2022-04-15
US63/331,773 2022-04-15
PCT/US2023/065784 WO2023201340A2 (en) 2022-04-15 2023-04-14 Compositions and methods for reducing cell therapy immunogenicity

Publications (2)

Publication Number Publication Date
JP2025513894A JP2025513894A (ja) 2025-04-30
JP2025513894A5 true JP2025513894A5 (cg-RX-API-DMAC7.html) 2026-04-22

Family

ID=88330399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560753A Pending JP2025513894A (ja) 2022-04-15 2023-04-14 細胞療法の免疫原性を低下させるための組成物及び方法

Country Status (6)

Country Link
US (1) US20250325585A1 (cg-RX-API-DMAC7.html)
EP (1) EP4508197A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025513894A (cg-RX-API-DMAC7.html)
AU (1) AU2023254114A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249063A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023201340A2 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
WO2020018708A1 (en) * 2018-07-18 2020-01-23 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
CA3106980A1 (en) * 2018-07-22 2020-01-30 Health Research, Inc. Major histocompatibility complex class ll-expressing cancer cell vaccine and methods of use for producing integrated immune responses
EP4150058A4 (en) * 2020-05-13 2024-06-19 Nanjing Legend Biotech Co., Ltd. COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENIC CELLS USING MONKEY ICP47 AND VARIANTS THEREOF

Similar Documents

Publication Publication Date Title
CN109485734B (zh) 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
JP2021000103A5 (cg-RX-API-DMAC7.html)
JP2021520788A5 (cg-RX-API-DMAC7.html)
AU2023201162A1 (en) Compositions and methods for immunooncology
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
JP2018527014A5 (cg-RX-API-DMAC7.html)
EP3116902B1 (en) Method for generating t-cells compatible for allogenic transplantation
US20220348929A1 (en) Crispr abasic restricted nucleotides and crispr accuracy via analogs
WO2021163618A1 (en) Method of predicting response to chimeric antigen receptor therapy
RU2017105065A (ru) Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
RU2017108903A (ru) Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
JP2019515661A5 (cg-RX-API-DMAC7.html)
JP2017522879A5 (cg-RX-API-DMAC7.html)
JP2017527271A5 (cg-RX-API-DMAC7.html)
RU2017105161A (ru) Лечение рака с использованием химерного антигенного рецептора cll-1
JP2022512882A5 (cg-RX-API-DMAC7.html)
JP2022530773A5 (cg-RX-API-DMAC7.html)
JP2021530233A5 (cg-RX-API-DMAC7.html)
RU2019128921A (ru) Антитело к il-13ra2 и его применение
EP3508504A1 (en) Human-cd123-targeting chimeric receptor ligand and application thereof
EP4055049A1 (en) Bcma-targeted car-t cell therapy of multiple myeloma
JP2022538425A5 (cg-RX-API-DMAC7.html)
JP2020500903A5 (cg-RX-API-DMAC7.html)
JP2023518930A5 (cg-RX-API-DMAC7.html)
CN118221828B (zh) Car分子、car细胞和car药物组合物及其应用